Rigel Pharmaceuticals Appoints Michael Miller to Accelerate Commercial Expansion and In‑Licensing

Rigel taps industry veteran to drive commercial expansion

Board addition intended to accelerate product growth and in‑licensing

Rigel Pharmaceuticals appoints Michael P. Miller to its board, a move the South San Francisco biotech says reinforces its push to scale commercial operations and broaden its pipeline through in‑licensing. The company says Miller’s four decades of commercial and leadership experience will support a transformational strategic plan focused on growing its marketed medicines and evaluating external opportunities to add new assets.

President and CEO Raul Rodriguez says Miller’s background in commercial execution aligns with Rigel’s objective to convert its existing portfolio into broader patient access while maintaining momentum in development programs. The company frames the appointment as part of a wider effort to leverage a profitable commercial engine to fund and advance potential therapies for hematologic disorders and oncology, and to position Rigel for expanded market reach.

The board addition signals a strategic inflection point for Rigel as it balances near‑term commercialization with longer‑term development. Management emphasizes the practical value of senior commercial leadership in negotiating partnerships, executing launches, and identifying in‑licensing targets that complement Rigel’s clinical priorities in blood diseases and cancer.

Veteran executive brings commercialization pedigree

Miller brings executive commercial experience from roles including Executive Vice President, U.S. Commercial at Jazz Pharmaceuticals, Senior Vice President and Chief Commercial Officer at Vivus, and leadership posts at Genentech, Connetics (acquired by Stiefel/GSK), ALZA (acquired by Johnson & Johnson) and Syntex. He also serves on the boards of Puma Biotechnology and BioXcel Therapeutics and holds degrees from the University of San Francisco and San Francisco State University.

Company profile and release details

Founded in 1996, Rigel markets products and advances a development pipeline aimed at improving outcomes for patients with hematologic and oncologic conditions. The announcement is distributed via PR Newswire from Rigel’s South San Francisco headquarters and reiterates the company’s mission to discover and provide novel therapies. Investor and media contact details accompany the release.